SECTION INTERNATIONAL BUSINESS, EUROPEAN INTEGRATION, FOREIGN LANGUAGES AND BUSINESS ENVIRONMENT

"EARLY-MOVER ADVANTAGE" VERSUS "SECOND TAKES MOST" DYNAMICS OF THE GLOBAL OBESITY-TREATING SECTOR

Adrian NEGREA, Daniel-Nicu IONAȘ

Department of International Business, Faculty of Economics, University of Oradea, Oradea, Romania
ngr_adrian@yahoo.com
ionasdanieln@gmail.com

Abstract: *The pharmaceutical landscape for obesity treatments is defined by extreme market volatility and risks, where clinical trial data and regulatory milestones serve as the primary catalysts for multi-billion dollar shifts in valuation. Recent market shifts illustrate a transition from early-mover advantages to a regime dictated by clinical superiority and manufacturing scale, as evidenced by Eli Lilly surpassing Novo Nordisk in market capitalization; while analysis of various market scenarios reveals that while positive Phase 2/3 data can double the value of clinical-stage companies, established leaders face significant risks from "multiple compression," competitive displacement, and the emergence of lower-priced copycat medications. Furthermore, a strategic focus on the GLP-1/GIP receptor space is currently rewarded with valuation premiums; while resource diversification often leads to institutional divestment and stagnant growth; which sometimes can lead to market loss.*

Keywords: *Obesity Therapeutics; GLP-1/GIP; Pharmaceutical Valuation; Clinical Trial Catalysts; Market Capitalization; Competitive Displacement; Multiple Compression*

JEL Classification: *L65; G14; O32; L11*

1. Introduction

The global pharmaceutical industry is currently engaged in an "Obesity Gold Rush," a winner-takes-most market dynamic where the development of high-efficacy metabolic therapies has become the primary driver of sector growth. The valuation of companies within this space; ranging from established giants like Eli Lilly and Novo Nordisk to emerging clinical-stage companies like Viking Therapeutics, is a direct reflection of predicted clinical efficacy and real-world molecule performance with very small margins between sinking and swimming above the water line. As time-to-market becomes the critical determinant of long-term success, early entrants have sought to solidify their positions through "compounding advantages," including physician familiarity and long-term payer relationships; a strategy proved to "shut the door behind"; leaving back the ones who did not have the capital or strategy to be earlier in the game. However, the landscape remains precarious as the binarity

nature of clinical outcomes means that even minor fails to demonstrate superiority or the discovery of safety signals can result in catastrophic equity collapses and this document examines four primary scenarios: product launches, competitive displacement, clinical setbacks, and strategic hesitation; analyzing how scientific developments translates into financial volatility within the obesity market.

2.1 Scenario 1: Equity Value Rise during Primary and Secondary Product Launches

The release of a new obesity treatments; whether it is an initial FDA approval, a secondary label expansion, or the publication of pivotal Phase 2/3 data serves as the most potent catalyst for market capitalization growth. The valuation of a company in this space is often a direct reflection of its clinical estimations or the predicted efficacy of its molecules in real-world scenarios.

The data illustrates an interesting divergence in valuation drivers: for clinical-stage companies like Viking and Structure Therapeutics, successful Phase 2 results function as massive enterprise value re-rating events, often doubling market capitalization in a single session by pricing in future acquisition premiums. In the contrast, for established leaders, share value is increasingly sensitive to "multiple compression" risks and capital rotation.

For instance, while Novo Nordisk remains the most valuable company in Europe, it was surpassed by Eli Lilly in the race to the trillion-dollar market capitalization because Eli Lilly captured a dominant 60.5% share of the U.S. obesity and diabetes market and investors currently value Eli Lilly at over 50 times its expected earnings; a growth driven by forecasts of up to $83 billion in revenue for 2026. In contrast, Novo Nordisk’s market value plummeted from a peak of $659 billion in 2024 to approximately $259 billion by early 2026, as the company warned investors of a potential 13% decline in profits due to a looming price war and the rise of cheaper copycat medications (Raghunath, 2026).

2.2 Scenario 2: Competitive Displacement and the Erosion of Early-Mover Premiums

The obesity market is increasingly competitive and hard to stay relevant and the release of a superior product by a competitor usually triggers a significant sell-off in existing market leaders. This displacement risk is quantified through changes in market share and P/E multiple compression; as we are going to see below.

The competitive landscape shifted in favor of Eli Lilly at the end of 2025 when Eli Lilly successfully increased its share of the U.S. obesity and diabetes drug market to 60.5%, while Novo Nordisk’s share fell to 39.1% during the same period (Raghunath, 2026). This share loss was accompanied by Novo Nordisk’s warning that sales and profits could decline by up to 13% in 2026 due to intensifying pricing pressures.

The financial impact of competitive stumbles is most visible in head-to-head efficacy comparisons; as in February 2026 Novo Nordisk reported that its combo drug CagriSema acheived a 23% weight loss after 84 weeks. However, this was insufficient to demonstrate superiority to Lilly’s Zepbound, which achieved a 25.5% weight reduction (Andersen, 2026) and consequently, Novo Nordisk’s stock fell over 16% to 251.4DKK, its lowest closing price since June 2021 (Ritzau, 2026). This fenomenon led analysts to low their fair value estimates for Novo Nordisk as the high-dose strategy was perceived to be under pressure from Lilly’s superior efficacy profile (Andersen, 2026).

Valuations are also vulnerable to the entry of non-traditional competitors utilizing the compounding pharmacy loophole. Here, Novo Nordisk shares fell 21% in a single week after Hims & Hers Health (HIMS) launched a lower-priced copycat version of the Wegovy pill (TradingView, 2026). This entry forced a re-evaluation of Novo's market value, which retracted from a peak of approximately US$ 659 billion in June 2024 to just over US$ 200 billion by February 2026 (TradingView, 2026).

2.3 Scenario 3: Market Collapse Following Clinical Setbacks

On the 23rd of February 2026 Novo Nordisk (NVO) suffered a historic 16.43% single-day decline after its combo drug CagriSema achieved "only" 23.0% weight loss compared to 25.5% of Lilly's Zepbound, failing to demonstrate superiority (Livingston, 2026). This failure forced the stock to 251 DKK, its lowest close since 2021 (Ohlen, 2026).

Another case being Pfizer (PFE). It saw its obesity strategy dismantled by safety signals when following the termination of lotiglipron in 2023, Pfizer discontinued its once-daily danuglipron in April 2025 due to liver toxicity concerns. This hollowed out their pipeline, leaving Pfizer with no real product against AstraZeneca, Eli Lilly, Novo Nordisk, Structure Therapeutics and Viking Therapeutics (Taylor, 2025).

Last but not least, an experimental obesity shot from both Roche Holding AG and Zealand Pharma A/S failed to meet industry expectations in a study, throwing shadows on their prospects of competing in the fast-growing market and sending their shares lower. Notably, the duo said the petrelintide shot delivered 10.7% weight loss after 42 weeks of treatment, well short of results for existing treatments from Eli Lilly and Novo Nordisk who are situated at 23% and 25.5% respectively. The drug showed little side effects (similar to placebo); but the investor was disappointed in the main comparison; which is the weight-loss percentages and as a result shares of Zealand dropped by a record 32%, while Roche fell as much as 3.3% in early trading Friday (Bloomberg, 2026).

2.4 Scenario 4: Missed Launch Dates and Resource Diversion: The Opportunity Cost of Strategic Hesitation

The "Obesity Gold Rush" is characterized by a winner-takes-most market dynamic where time-to-market is the primary determinant of long-term valuation. In this environment, strategic pivots away from metabolic R&D—even toward traditionally high-value sectors like oncology—are increasingly viewed by the capital markets as a failure to capture generational growth.

2.4.1 The Mechanics of Opportunity Cost and Investor Penalties

In the pharmaceutical world and valuation, opportunity cost is not merely a theoretical loss; but rather a measurable "penalty" reflected in share price and institutional divestment and investors reward companies that demonstrate a singular focus on the GLP-1/GIP receptor space due to the Total Addressable Market; rather than "scattering" their shots all over the place.

On 14th of December 2023 Pfizer acquired Seagen for $43 billion and since early 2025, Pfizer's stock has declined by 17% a consequence of the company lacking a viable, competitive obesity pill while its peers achieved clinical breakthroughs (Nasdaq).

2.4.2 The "Compounding Advantage" of Early Entrants

The delay in product launches creates a structural disadvantage known as the "compounding advantage." Early leaders, specifically Eli Lilly and Novo Nordisk, have utilized their lead time to establish two critical pillars: the Physician Familiarity where clinicians develop prescribing comfort and "brand loyalty" based on safety data and patient outcomes that have been longitudinal for several years (DrugPatentWatch, 2025); Payer Relationships where Early movers secure multi-year contracts with Pharmacy Benefit Managers (PBMs) and insurers; by the time late-movers finally arrive, the market is usually locked behind preferred-tier status for incumbents (Fierce Pharma) and finally manufacturing scales (Buntz, 2026). Missing these scale-up deadlines results in a permanent loss of market share that cannot be recovered simply by releasing a "me-too" drug later in the cycle.

2.4.3 Valuation Divergence: "Going All-In" vs. Diversification

The market currently applies a premium to companies that prioritize obesity over a diversified portfolio. This is evidenced by the stark contrast in revenue guidance and market sentiment: Eli Lilly is at $80B–$83B (*Eli Lilly Issues FY26 Guidance | Nasdaq*, n.d.) with the strategic focus on Obesity & Diabetes (all in) and ~25% revenue growth projection (Dunleavy, 2026), while Pfizer is stagnant (*Pfizer Projects 2026 Revenue of $59.5-62.5 Billion, Adjusts 2025 Outlook By Investing.Com*, n.d.) with the focus diversified between oncology and vaccines, and as an result the stock is on decline since 2025 (*Why Pfizer Stock Dropped Today | Nasdaq*, n.d.).

Investors view Lilly's 25% revenue increase as a validation of their execution on scale-up deadlines. Conversely, Pfizer's struggle to stabilize its internal GLP-1 candidates, like the twice-daily danuglipron, highlights the risk of "resource dilution" where capital is spread across acquisitions rather than focused on high-velocity metabolic R&D which could increase revenue in the future.

3. Conclusions

The financial evolution of the anti-obesity drug market highlights that maintaining a leadership position is directly linked to continuous innovation and clinical excellence and unwavering strategic commitment. While pioneers such as Novo Nordisk established this market, the subsequent erosion of their premiums relative to competitors like Eli Lilly underscores the fragility of market share when confronted with superior efficacy data, trial results and and pricing pressures from non-traditional rivals. Clinical setbacks, such as those experienced by Pfizer and Zealand Pharma, demonstrate the high opportunity cost associated with R&D pipeline failures, which can drastically impair corporate value and deprive businesses of viable growth avenues.

Finally, capital markets significantly reward "all-in" metabolic strategies while simultaneously punishing diversification into other sector and this suggests that the capacity to scale production and sustain high R&D momentum represents the only viable path for maintaining trillion-dollar market capitalizations in the modern pharmaceutical era; however difficult and unachievable that may seem.

References

1. Andersen, K. (2026, February 24). *Novo Nordisk: Another Disappointing Cagrisema Trial Adds Pressure to High-Dose Strategy | Morningstar UK*. Morningstar, Inc. https://global.morningstar.com/en-gb/stocks/novo-nordisk-another-disappointing-cagrisema-trial-adds-pressure-high-dose-strategy
2. Bloomberg. (2026, March 6). Zealand Plunge Pulls Roche Lower After Obesity Shot Disappoints. *SWI Swissinfo.Ch*. https://www.swissinfo.ch/eng/zealand-plunge-pulls-roche-lower-after-obesity-shot-disappoints/91049650
3. Buntz, B. (2026, January 5). Novo Nordisk launches first GLP-1 pill for obesity, but Lilly may dominate the oral market eventually. *Drug Discovery and Development*. https://www.drugdiscoverytrends.com/novo-nordisk-launches-first-glp-1-pill-for-obesity-but-lilly-may-dominate-the-oral-market-eventually/
4. DrugPatentWatch. (2025, August 5). *Is There a First-Mover Advantage for Biosimilars?* DrugPatentWatch – Transform Data into Market Domination. https://www.drugpatentwatch.com/blog/is-there-a-first-mover-advantage-for-biologics/
5. Dunleavy, K. (2026, February 4). *Lilly sees big sales increase in 2026 despite pricing pressures*. https://www.fiercepharma.com/pharma/even-pricing-headwinds-eli-lilly-expects-sales-continue-surge-2026
6. *Eli Lilly Issues FY26 Guidance | Nasdaq*. (n.d.). Retrieved March 8, 2026, from https://www.rttnews.com/3617301/eli-lilly-issues-fy26-guidance.aspx
7. Fick, M. (2023, May 3). Analysis-Investors see big Novo Nordisk stock boost if obesity drug shows heart benefit. *Y100 WNCY | Your Home For Country & Fun | Green Bay, WI*. https://wncy.com/2023/05/03/analysis-investors-see-big-novo-nordisk-stock-boost-if-obesity-drug-shows-heart-benefit/
8. Fox, M. (2024, February 27). *Viking Therapeutics soars 104% after its GLP-1 weight-loss drug posts impressive results in Phase 2 trial*. Markets Insider. https://markets.businessinsider.com/news/stocks/viking-therapeutics-stock-price-double-glp-1-weight-loss-drug-2024-2
9. Gardner, J. (2024, February 27). *Viking data suggest obesity drug could rival Zepbound, Wegovy | BioPharma Dive*. Biopharmadive. https://www.biopharmadive.com/news/viking-obesity-drug-study-results-zepbound-wegovy/708622/
10. Livingston, R. (2026, February 23). *CagriSema Demonstrates Weight Loss, Fails to Achieve Primary Endpoint Compared to Tirzepatide | HCPLive*. https://www.hcplive.com/view/cagrisema-demonstrates-weight-loss-fails-to-achieve-primary-endpoint-compared-to-tirzepatide
11. Ohlen, E. (2026, February 23). *Novo Nordisk sinks 16% after weight loss drug fails to match Eli Lilly's in trial*. CNBC. https://www.cnbc.com/2026/02/23/novo-nordisk-stock-cagrisema-trial-fails-weight-loss.html
12. Pagliarulo, N., & Gardner, J. (2025, November 21). *Eli Lilly becomes first drugmaker to hit $1 trillion in market value | BioPharma Dive*. Biopharmadive. https://www.biopharmadive.com/news/eli-lilly-1-trillion-pharmaceutical-market-value-obesity/721819/
13. *Pfizer projects 2026 revenue of $59.5-62.5 billion, adjusts 2025 outlook By Investing.com*. (n.d.). Investing.Com UK. Retrieved March 8, 2026, from

https://uk.investing.com/news/company-news/pfizer-projects-2026-revenue-of-595625-billion-adjusts-2025-outlook-93CH-4419462
14.Raghunath, A. (2026, February 5). *Eli Lilly Stock Spikes 10% as Strong Zepbound Demand Drives Robust 2026 Sales Forecast*. TIKR.Com. https://www.tikr.com/blog/eli-lilly-nyse-lly-stock-spikes-strong-zepbound-demand-robust-2026-sales-forecast
15.Reuters. (2025a, November 21). *Eli Lilly becomes first pharma firm to join $1 trillion club*. Al Jazeera. https://www.aljazeera.com/economy/2025/11/21/eli-lilly-becomes-first-pharma-firm-to-join-1-trillion-club
16.Reuters. (2025b, December 23). *Novo Nordisk shares jump almost 8% after*. BNN Bloomberg. https://www.bnnbloomberg.ca/business/2025/12/23/novo-nordisk-shares-jump-almost-8-after-us-approves-wegovy-pill/
17.Ritzau. (2026, February 24). Novo stock closes at 2021 low on weight loss data. *The Copenhagen Post*. https://cphpost.dk/2026-02-24/general/novo-stock-closes-at-2021-low-on-weight-loss-data/
18.Stock Titan. (2026, January 5). *Daily weight loss pill shows ~17% drop in trial, starts at about $5 a day*. Stock Titan. https://www.stocktitan.net/news/NVO/novo-nordisk-s-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-s0kgzs2bzk5n.html
19.Taylor, N. P. (2025, April 14). *Pfizer axes oral GLP-1 asset, blowing hole in obesity plan*. https://www.fiercebiotech.com/biotech/pfizer-axes-oral-glp-1-asset-over-liver-injury-blowing-hole-obesity-plan
20.TradingView. (2025, December 8). *Structure Therapeutics stock: What's driving sudden 103% jump in GPCR shares?* TradingView. https://www.tradingview.com/news/invezz:4e2be52dc094b:0-structure-therapeutics-stock-what-s-driving-sudden-103-jump-in-gpcr-shares/
21.TradingView. (2026, February 6). *Novo Nordisk Shares Slide 21% After Forecast Cut, Copycat Wegovy Pill Launch*. TradingView. https://www.tradingview.com/news/gurufocus:f9ae04648094b:0-novo-nordisk-shares-slide-21-after-forecast-cut-copycat-wegovy-pill-launch/
22.*Why Pfizer Stock Dropped Today | Nasdaq*. (n.d.). Retrieved March 8, 2026, from https://www.fool.com/investing/2026/02/03/why-pfizer-stock-dropped-today/
23.Zacks Equity Research. (2025, December 9). *GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron | Nasdaq*. NASDAQ. https://www.nasdaq.com/articles/gpcr-stock-soars-102-strong-phase-ii-obesity-data-aleniglipron